![Charles Gillies O'Bryan-Tear](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Charles Gillies O'Bryan-Tear
Président chez
ONCOINVENT ASA
Profil
Charles Gillies O'Bryan-Tear is currently Chairman at Oncoinvent ASA since 2024 and Director at Eridge House (Holdings) Ltd. since 2017.
Former roles include Chairman at Oncoinvent ASA (Old), Medical Director at Bristol-Myers Squibb Pharmaceuticals Ltd., Director at Affibody AB, Director at Fusion Pharmaceuticals, Inc. from 2019 to 2023, Interim Medical Director at Genzyme Therapeutics Ltd., Non-Executive Director at Clarity Pharmaceuticals Ltd. from 2019 to 2023, Vice President-Research & Development at GlaxoSmithKline Biologicals SA, Chief Medical Officer at Scancell Holdings Plc, and Chief Medical Officer at Algeta ASA from 2009 to 2014.
Education includes an MBA from Cranfield School of Management and undergraduate studies at the University of Cambridge.
Postes actifs de Charles Gillies O'Bryan-Tear
| Sociétés | Poste | Début |
|---|---|---|
| ONCOINVENT ASA | Président | 01/01/2024 |
Eridge House (Holdings) Ltd.
 Eridge House (Holdings) Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Directeur/Membre du Conseil | 02/11/2017 |
Anciens postes connus de Charles Gillies O'Bryan-Tear
| Sociétés | Poste | Fin |
|---|---|---|
| CLARITY PHARMACEUTICALS LTD | Directeur/Membre du Conseil | 15/05/2023 |
| FUSN PHAR | Directeur/Membre du Conseil | 01/05/2023 |
| ALGETA ASA | Directeur Technique/Scientifique/R&D | 01/01/2014 |
Oncoinvent AS
 Oncoinvent AS Pharmaceuticals: MajorHealth Technology Develops alpha-emitting radiopharmaceuticals for cancer treatment | Président | - |
| SCANCELL HOLDINGS PLC | Directeur Technique/Scientifique/R&D | - |
Formation de Charles Gillies O'Bryan-Tear
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
9
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Bristol-Myers Squibb Pharmaceuticals Ltd.
 Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Affibody AB
 Affibody AB BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops radioligand therapies for cancer treatment | Health Technology |
GlaxoSmithKline Biologicals SA
 GlaxoSmithKline Biologicals SA BiotechnologyHealth Technology Operates biopharma and pharmaceutical company | Health Technology |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Engages in the development of products for the treatment of cancer | Health Technology |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Scancell Holdings Plc
 Scancell Holdings Plc BiotechnologyHealth Technology Develops therapeutic cancer vaccines | Health Technology |
BerGenBio ASA
 BerGenBio ASA Pharmaceuticals: MajorHealth Technology Develops drugs for aggressive, drug resistant cancers | Health Technology |
Cranfield School of Management
 Cranfield School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Develops alpha-emitting radiopharmaceuticals for cancer treatment | Health Technology |
Clarity Pharmaceuticals Ltd.
 Clarity Pharmaceuticals Ltd. Medical SpecialtiesHealth Technology Develops radiopharmaceutical products | Health Technology |
Fusion Pharmaceuticals, Inc.
 Fusion Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals for the treatment of cancer | Health Technology |
Eridge House (Holdings) Ltd.
Eridge House (Holdings) Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Finance |
